Abstract: An artificial intelligence (AI) system classifies a document by a document type and determines redlining for the document based on the classified document type. The AI system may use machine learning to classify the document, where the AI system trains a machine-learned model using training documents of respective types. After determining the document type of a target document, the AI system compares the target document against one or more templates of the classified document type to determine edited or unedited portions of the target document. The AI system can modify an unedited portion of the target document using a predetermined edit associated with a template. The modified document target document may be displayed at a client device such that the edits (e.g., the modified unedited portion and existing edits in the target document) are visually distinct from one another.

Abstract: An artificial intelligence (AI) system accesses training text documents and parses the training text documents to extract training edits. The AI system forms a set of training data that includes the training text documents and the training edits. The AI system trains an AI model based on at least the set of training data. The AI system may also use a reference model, a general model, and/or user input to generate the AI model. In some embodiments, the training text documents are associated with a type of transaction and the AI model is specific to the type of transaction. The AI system applies the AI model to a target text document to generate target edits. The AI system further modifies the target text document to include the target edits and transmits the modified target text document to a client device.

Abstract: The present invention is directed towards new 18F-folate radiopharmaceuticals, wherein fluorine-18 is covalently linked to the glutamate portion of a folate or derivative thereof, a method of their preparation, as well as their use in diagnosis and monitoring of therapy of cancer and inflammatory and autoimmune diseases.

Abstract: The present invention is directed towards a new method of synthesis of 18F-folate radiopharmaceuticals, wherein fluorine-18 is attached to a pteroate (or folate) or derivative thereof, through direct radiolabeling with 18[F]fluoride, as well as 18F-folate radiopharmaceuticals obtained by such method of synthesis and their use in diagnosis and monitoring of cancer therapy and therapy of inflammatory and autoimmune diseases.

Abstract: The present invention is directed towards new 18F-folate radiopharmaceuticals, wherein fluorine-18 is covalently linked to the glutamate portion of a folate or derivative thereof, a method of their preparation, as well as their use in diagnosis and monitoring of therapy of cancer and inflammatory and autoimmune diseases.

Abstract: The present invention is directed towards new 18F-folate radiopharmaceuticals, wherein the fluorine-18 is covalently linked to the aminobenzoyl moiety, which connects the condensed pyrimidine heterocycle to the amino acid portion within folate structures, as well as their precursors and their non-radioactive references, a method of their preparation, as well as their use in diagnosis of a cell or population of cells expressing a folate-receptor and monitoring of cancer and inflammatory and autoimmune diseases and therapy thereof.

Abstract: The present invention is directed towards new 18F-folate radiopharmaceuticals, wherein the fluorine-18 is covalently linked to the aminobenzoyl moiety, which connects the condensed pyrimidine heterocycle to the amino acid portion within folate structures, as well as their precursors and their non-radioactive references, a method of their preparation, as well as their use in diagnosis of a cell or population of cells expressing a folate-receptor and monitoring of cancer and inflammatory and autoimmune diseases and therapy thereof.

Abstract: The present invention is directed towards new 18F-folate radiopharmaceuticals, wherein the fluorine-18 is covalently linked to the aminobenzoyl moiety, which connects the condensed pyrimidine heterocycle to the amino acid portion within folate structures, as well as their precursors and their non-radioactive references, a method of their preparation, as well as their use in diagnosis of a cell or population of cells expressing a folate-receptor and monitoring of cancer and inflammatory and autoimmune diseases and therapy thereof.

Abstract: The present invention is directed towards a new method of synthesis of 18F-folate radiopharmaceuticals, wherein fluorine-18 is attached to a pteroate (or folate) or derivative thereof, through direct radiolabeling with 18[F]fluoride, as well as 18F-folate radiopharmaceuticals obtained by such method of synthesis and their use in diagnosis and monitoring of cancer therapy and therapy of inflammatory and autoimmune diseases.

Abstract: An optical assembly, which is in particular in the form of a splitter component with a so-called splitter forming a passive optical component, is produced particularly inexpensively. In a first step a plurality of splitters are produced on a common wafer by forming a corresponding conductor track pattern. In a second step optical fibers are coupled simultaneously to the connection sides of the individual splitters with the aid of a connection carrier. Then, in a third step the individual splitters with the connection carriers connected thereto are separated form one another. Only one common coupling operation for a large number of splitters is required. The splitters may then be connected to form a splitter cascade.

Abstract: The present invention is directed towards new 18F-folate radiopharmaceuticals, wherein fluorine-18 is covalently linked through a triazole- or tetrazole linker to a folate or derivative thereof, a method of their preparation, as well as their use in diagnosis and monitoring of therapy of cancer and inflammatory and autoimmune diseases.

Abstract: An optical assembly, which is in particular in the form of a splitter component with a so-called splitter forming a passive optical component, is produced particularly inexpensively. In a first step a plurality of splitters are produced on a common wafer by forming a corresponding conductor track pattern. In a second step optical fibers are coupled simultaneously to the connection sides of the individual splitters with the aid of a connection carrier. Then, in a third step the individual splitters with the connection carriers connected thereto are separated form one another. Only one common coupling operation for a large number of splitters is required. The splitters may then be connected to form a splitter cascade.

Abstract: The present invention is directed towards new 18F-folate radiopharmaceuticals, wherein fluorine-18 is covalently linked to the glutamate portion of a folate or derivative thereof, a method of their preparation, as well as their use in diagnosis and monitoring of therapy of cancer and inflammatory and autoimmune diseases.

Abstract: The present invention is directed towards new 18F-folate radiopharmaceuticals, wherein fluorine-18 is covalently linked through a triazole- or tetrazole linker to a folate or derivative thereof, a method of their preparation, as well as their use in diagnosis and monitoring of therapy of cancer and inflammatory and autoimmune diseases.

Abstract: The present invention is directed towards a new method of synthesis of 18F-folate radiopharmaceuticals, wherein fluorine-18 is attached to a pteroate (or folate) or derivative thereof, through direct radiolabeling with 18[F]fluoride, as well as 18F-folate radiopharmaceuticals obtained by such method of synthesis and their use in diagnosis and monitoring of cancer therapy and therapy of inflammatory and autoimmune diseases.

Abstract: The present invention is directed towards new 18F-folate radio-pharmaceuticals, wherein the fluorine-18 is covalently linked to the aminobenzoyl moiety, which connects the condensed pyrimidine heterocycle to the amino acid portion within folate structures, as well as their precursors and their non-radioactive references, a method of their preparation, as well as their use in diagnosis of a cell or population of cells expressing a folate-receptor and monitoring of cancer and inflammatory and autoimmune diseases and therapy thereof.

Abstract: A method of production of mono- or multimodal lightwave guides from special substrate glasses of the glass system SiO.sub.2 -B.sub.2 O.sub.3 -Al.sub.2 O.sub.3 - K.sub.2 O-F.sup.-, with partial exchange of the Li.sup.+, Na.sup.+, and/or K.sup.+ ions present in the glass against Cs.sup.+ ions, the substrate glasses having the following compositions (in mol.-%): SiO.sub.2 45-72, B.sub.2 O.sub.3 8-25, Al.sub.2 O.sub.3 1-25, Li.sub.2 O 0-1, Na.sub.2 O 0-2, K.sub.2 O 6-18, MO 0-1 (MO= MgO, CaO, SrO, BaO, ZnO, PbO), in which a portion of the O.sup.- ions present in the glass are replaced by 1-15 mol % F.sup.- ions.

Abstract: Production of mono- or multimodal lightwave guides from special substrate glasses of the glass system SiO.sub.2 --B.sub.2 O.sub.3 --Al.sub.2 O.sub.3 -- K.sub.2 O--F.sup.-, with partial exchange of the Li.sup.+, Na.sup.+, and/or K.sup.+ ions present in the glass against Cs.sup.+ ions, the substrate glasses having the following compositions (in mol.-%): SiO.sub.2 45-72, B.sub.2 O.sub.3 8-25, Al.sub.2 O.sub.3 1-25, Li.sub.2 O 0-1, Na.sub.2 O 0-2, K.sub.2 O 6-18, MO 0-1 (MO=MgO, CaO, SrO, BaO, ZnO, PbO), in which a portion of the O.sup.- ions present in the glass are replaced by 1-15 mol % F.sup.- ions.

Abstract: A new, CdO-and ThO.sub.2 -free optical glass with refractive indices of 1.73-1.78 and Abbe numbers of 30-34 and with particularly good devitrification stability comprises (in weight %):______________________________________ SiO.sub.2 12-20, B.sub.2 O.sub.3 10-18, PbO 50-60 Al.sub.2 O.sub.3 2-7, ZnO 0-4, ZrO.sub.2 0.5-3 La.sub.2 O.sub.3 2-10, Cs.sub.2 O 0-5, M.sub.2 O 0-1 (M.sub.2 O.dbd. Na.sub.2 O, K.sub.2 O, Li.sub.2 O) TiO.sub.2 0-5 with the SiO.sub.2 /B.sub.2 O.sub.3 -ratio being about 1.0 to ______________________________________ 1.5.

Abstract: An optical glass, n.sub.d .gtoreq.1.60 and v.sub.d .gtoreq.58, having a high chemical stability as well as resistance to phase separation and crystallization, comprises in percent by weight:______________________________________ SiO.sub.2 21.5-27.0; B.sub.2 O.sub.3 23.5-30.0 SrO 16.0-24.0; La.sub.2 O.sub.3 10.0-20; Al.sub.2 O.sub.3 1.5-5.0; BaO 5.0-14.0; ZrO.sub.2 0-4.0; Li.sub.2 O 0.5-5.0; Na.sub.2 O 0.8-2.5; K.sub.2 O 0-2.0.